About Nivalis
Nivalis is a company based in Boulder (United States) founded in 2007 was acquired by Alpine Immune Sciences in April 2017. Nivalis has raised $50 million across 5 funding rounds from investors including Alpine Immune Sciences, RA Capital and Jennison Associates. Nivalis operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Boulder, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$50 M (USD)
in 5 rounds
-
Latest Funding Round
$30 M (USD), Series C
Nov 24, 2014
-
Investors
Alpine Immune Sciences
& 8 more
-
Employee Count
Not available
-
Acquired by
Alpine Immune Sciences
(Apr 18, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Nivalis
Nivalis has successfully raised a total of $50M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nivalis
Nivalis has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Alpine Immune Sciences, RA Capital and Jennison Associates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Venture and private equity investments are managed with global diversification.
|
Locked | Locked | Locked |
Investor details for Nivalis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nivalis
Investment portfolio details for Nivalis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nivalis
Detailed financials for Nivalis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nivalis Comparisons
Peer comparison for Nivalis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nivalis
Nivalis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
Detailed competitors of Nivalis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nivalis
Complete news archive for Nivalis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nivalis
Nivalis was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Nivalis is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Nivalis is a funded company, having raised a total of $50M across 5 funding rounds to date.
Nivalis was founded in 2007 in Boulder, United States, within the biotechnology sector. Small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) are developed by the company for cystic fibrosis treatment. Focus is placed on patients homozygous for the F508del mutation in the CFTR gene. The lead candidate has advanced to phase II clinical trials, addressing clinical needs in this area.
Nivalis's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
Nivalis has 9 investors. Key investors include Alpine Immune Sciences, RA Capital, Jennison Associates, Rock Springs Capital, and Deerfield.